BioGaia AB is a healthcare company. It develops, markets and sells probiotic products. The company segmented its operating activities into three reportable segments, Pediatrics, Adult Health, and other. Pediatrics segment comprised of digestive health tablets, oral rehydration solution, and cultures as an ingredient in a licensee’s product and royalties from pediatric health products. Adult Health business unit comprises digestive health tablets, oral health lozenges, cultures as an ingredient in a licensee’s dairy products. The other segment consists of royalties in respect of development projects and animal health products. Its primary geographic markets are Europe, USA and Canada, Asia, and Rest of World.

Key Stats
- Website: https://www.biogaia.se
- Headquarters: Sweden
- Employees: 157
- Market Cap (at close 21/08/2023): SEK 9.81Bil
- Morningstar Sector: Healthcare
- Morningstar Industry: Drug Manufacturers - Specialty & Generic
- Stock Style: Small-Growth
- Fiscal Year Ends: December

Company Profile
BioGaia AB is a healthcare company. It develops, markets and sells probiotic products. The company segmented its operating activities into three reportable segments, Pediatrics, Adult Health, and other. Pediatrics segment comprised of digestive health tablets, oral rehydration solution, and cultures as an ingredient in a licensee’s product and royalties from pediatric health products. Adult Health business unit comprises digestive health tablets, oral health lozenges, cultures as an ingredient in a licensee’s dairy products. The other segment consists of royalties in respect of development projects and animal health products. Its primary geographic markets are Europe, USA and Canada, Asia, and Rest of World.

Financials (SEK)

<table>
<thead>
<tr>
<th>Years</th>
<th>5 Yr Trend</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue (Mil)</td>
<td></td>
<td>615</td>
<td>742</td>
<td>768</td>
</tr>
<tr>
<td>Gross Operating Profit (Mil)</td>
<td></td>
<td>463</td>
<td>556</td>
<td>564</td>
</tr>
<tr>
<td>Operating Income (Mil)</td>
<td></td>
<td>238</td>
<td>275</td>
<td>250</td>
</tr>
<tr>
<td>Operating Margin %</td>
<td></td>
<td>38.8</td>
<td>37.1</td>
<td>32.5</td>
</tr>
<tr>
<td>EBIT (Mil)</td>
<td></td>
<td>238</td>
<td>278</td>
<td>243</td>
</tr>
<tr>
<td>Income before income taxes (Mil)</td>
<td></td>
<td>233</td>
<td>278</td>
<td>242</td>
</tr>
<tr>
<td>Net Income (Mil)</td>
<td></td>
<td>181</td>
<td>215</td>
<td>187</td>
</tr>
<tr>
<td>Operating Cash Flow (Mil)</td>
<td></td>
<td>223</td>
<td>183</td>
<td>148</td>
</tr>
<tr>
<td>Free Cash Flow (Mil)</td>
<td></td>
<td>196</td>
<td>170</td>
<td>109</td>
</tr>
<tr>
<td>Basic Earn. Per Share</td>
<td></td>
<td>10.42</td>
<td>12.40</td>
<td>10.81</td>
</tr>
<tr>
<td>Dividend Per Share</td>
<td></td>
<td>3.16</td>
<td>9.00</td>
<td>4.05</td>
</tr>
</tbody>
</table>

Dividends (SEK)

<table>
<thead>
<tr>
<th>Ex Date</th>
<th>Payment</th>
<th>Type</th>
<th>Currency</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/05/2020</td>
<td>14/05/2020</td>
<td>Cash</td>
<td>SEK</td>
<td>3.75</td>
</tr>
<tr>
<td>09/05/2019</td>
<td>15/05/2019</td>
<td>Cash</td>
<td>SEK</td>
<td>4.05</td>
</tr>
<tr>
<td>09/05/2019</td>
<td>15/05/2019</td>
<td>Special</td>
<td>SEK</td>
<td>5.95</td>
</tr>
<tr>
<td>26/04/2018</td>
<td>03/05/2018</td>
<td>Cash</td>
<td>SEK</td>
<td>9.00</td>
</tr>
<tr>
<td>04/05/2017</td>
<td>10/05/2017</td>
<td>Cash</td>
<td>SEK</td>
<td>3.16</td>
</tr>
</tbody>
</table>

If data are missing or you find incorrect information in the Fact Sheet, please send an email to: support.nordics@morningstar.com

Please find the FAQ and Methodology at: www.nasdaqomxnordic.com/fact-sheet
**BioGaia AB**, BIOG B, (SE0000470395)

**Last Price SEK 566.00**

### Compound Annual Growth Rates (SEK)

<table>
<thead>
<tr>
<th>Period</th>
<th>Revenue %</th>
<th>Operating Income %</th>
<th>Earnings/Share %</th>
<th>Dividend Yield %</th>
<th>Net Income %</th>
<th>Operating Income %</th>
<th>Stock Total Return %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1Y</td>
<td>3.57</td>
<td>-12.82</td>
<td>-55.00</td>
<td>-36.82</td>
<td>-12.82</td>
<td>43.44</td>
<td>35.86</td>
</tr>
<tr>
<td>3Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40.80</td>
<td></td>
</tr>
<tr>
<td>5Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>42.19</td>
<td></td>
</tr>
<tr>
<td>10Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>42.19</td>
<td></td>
</tr>
</tbody>
</table>

### Profitability Analysis (SEK)

#### Current

- **Return on Equity**: 43.40%
- **Return on Assets**: 32.35%
- **Current Assets**: 124,942 SEK
- **Net PP&E**: 106,149 SEK
- **Intangibles**: 51,58
- **Total Assets**: 660,666 SEK
- **Accounts Payable**: 34,28
- **Current Debt**: 0
- **Current Liabilities**: 145,125
- **Long Term Debt (Mil)**: -
- **Total Liabilities**: -
- **Total Equity (Mil)**: 505,508

#### 3Y Avg

- **Return on Equity**: 42.77%
- **Return on Assets**: 34.31%
- **Current Assets**: 124,942 SEK
- **Net PP&E**: 106,149 SEK
- **Intangibles**: 51,58
- **Total Assets**: 660,666 SEK
- **Accounts Payable**: 34,28
- **Current Debt**: 0
- **Current Liabilities**: 145,125
- **Long Term Debt (Mil)**: -
- **Total Liabilities**: -
- **Total Equity (Mil)**: 505,508

#### 5Y Avg

- **Return on Equity**: 41.10%
- **Return on Assets**: 35.75%
- **Current Assets**: 124,942 SEK
- **Net PP&E**: 106,149 SEK
- **Intangibles**: 51,58
- **Total Assets**: 660,666 SEK
- **Accounts Payable**: 34,28
- **Current Debt**: 0
- **Current Liabilities**: 145,125
- **Long Term Debt (Mil)**: -
- **Total Liabilities**: -
- **Total Equity (Mil)**: 505,508

#### 10Y Avg

- **Return on Equity**: 38.38%
- **Return on Assets**: 36.38%
- **Current Assets**: 124,942 SEK
- **Net PP&E**: 106,149 SEK
- **Intangibles**: 51,58
- **Total Assets**: 660,666 SEK
- **Accounts Payable**: 34,28
- **Current Debt**: 0
- **Current Liabilities**: 145,125
- **Long Term Debt (Mil)**: -
- **Total Liabilities**: -
- **Total Equity (Mil)**: 505,508

### Financial Position (SEK, Mil)

- **Cash and cash equivalents**: 265,214
- **Deferred current assets**: 44,68
- **Current assets**: 124,942 SEK
- **Net PP&E**: 106,149 SEK
- **Intangibles**: 51,58
- **Total assets**: 660,666 SEK
- **Current liabilities**: 145,125
- **Working capital**: -
- **Long term debt**: -
- **Working capital**: -
- **Total equity**: 505,508

### Quarterly Results (SEK)

#### Revenue Mil

- **Most recent Q3**: 167,208 SEK
- **Prior year Q3**: 175,210 SEK
- **Revenue Growth % Q3 QoQ**: -24.82
- **Prior year Q3**: -13.05 QoQ
- **Earnings Per Share Q3**: 2.19 QoQ
- **Prior year Q3**: 2.97

### Options & Futures

- **Instrument**: Yes/No
- **Options**: Yes/No
- **Forwards**: Yes/No

For more information and prices go to: [www.nasdaqomxnordic.com/optionsandfutures](http://www.nasdaqomxnordic.com/optionsandfutures)

---

**Morningstar Disclaimer:** Morningstar makes no representations or warranties with respect to the Information and disclaims all liability for any use made of the contents of this document. Morningstar is not a fiduciary by virtue of any contract or otherwise. Morningstar is not responsible for any errors or omissions in the Information. All information is provided "as is" without warranty of any kind. Morningstar assumes no responsibility for any errors or omissions. Morningstar’s third party licensors do not constitute investment advice. Morningstar does not accept liability for any claims, losses or expenses arising out of the use of or reliance on this document, including without limitation losses arising from the use of its services. This document is intended for informational purposes only. Morningstar does not guarantee the security of the Information provided and make no warranties, express or implied, that the Information is error free, timely, accurate or contains no omissions. This document does not contain legal advice, nor does it constitute investment advice. Morningstar’s third party licensors do not constitute investment advice. Morningstar does not accept liability for any claims, losses or expenses arising out of the use of or reliance on this document.